Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPENTHE neoadjuvant pembrolizumab in high-risk thyroid cancers
2021-003524-32Phase 2Active
- Sponsor
- Istituti Clinici Scientifici Maugeri
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in thyroid cancer and well-differentiated thyroid cancer (WDTC), sponsored by Istituti Clinici Scientifici Maugeri. Primary endpoints: Objective tumor response, Near pathological complete remission and pathological complete remission and 1 more. Started Nov 2022; status: active.
02
Drugs
03
Conditions
thyroid cancerwell-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2021-003524-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003524-32.